Faculty Disclosures

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

Nature of Relevant Financial Relationship Last Name Role in Activity Commercial Interest What Was Received For What Role  Dragonfly, Fidia Pharma USA Inc.,  Honorarium  Consultant Bajorin Speaker Merck & Co., Sharp & Dohme,  Research Grants  Principle Investigator  Bristol‐Myers Squibb, Merck & Co.  Advanced Accelerator Applications, Blue Earth Diagnostics Limited, Curium SAS, GE Healthcare Janssen  Honorarium  Consultant Calais Speaker Pharmaceuticals, Progenics  Research Grants  Principle Investigator Pharmaceuticals  Honorarium  Speaker  Progenics Pharmaceuticals  Telix Pharmaceuticals

Gandara Speaker  None  N/A  N/A

 AbbVie Inc., Bristol‐Myers Squibb/Celgene  Akcea Therapeutics, Alnylam Pharmaceuticals, Ambry Genetics,  Data and Safety  Honorarium Amgen, Bristol‐Myers Monitoring Board  Honorarium Squibb/Celgene, Janssen  Consultant  Honorarium Gertz Speaker Pharmaceuticals, Karyopharm  Advisory Board  Research Grants Therapeutics, Prothena Corporation,  Investigator  Honorarium Research to Practice, Sanofi  Speaker  Stock Options  Ionis Pharmaceuticals  Advisory Board  Pfizer  i3 Health  Aurora Biopharma  AbbVie Inc., Amgen, Bristol‐Myers Squibb, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi  Actinium Pharmaceuticals  Research Grants  Research Support Kantarjian Speaker  AbbVie Inc., Adaptive  Honorarium  Advisory Board Biotechnologies, Amgen, Aptitude  Honorarium  Consultant/Speaker Health, Bio Ascend, Daiichi Sankyo, Delta Fly Pharma, Inc., Janssen Global, Novartis, Oxford Biomedical, Pfizer, Takeda

Kelton Speaker  None  N/A  N/A

 Bristol‐Myers Squibb, Eli Lilly, Merck  Honorarium  Advisory Board Klempner Speaker & Co., Pieris Pharmaceuticals  Honorarium  Consultant  Signatera, Inc.  Amgen, EMD Serono Inc., Genentech, Course Director,  Grants  Research Support Kosty Merck & Co. Moderator  Consulting Fees  Consultant  Biocept Inc.

Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology February 20‐21, 2021 ● Live Streaming Virtual Event

 Bluebird Bio, Global Blood Little Speaker  Research Support  Principle Investigator Therapeutics  Takeda  Honorarium  Consultant Ma Speaker  Takeda  Research Support  Safety Study  AbbVie Inc., Aprea, AstraZeneca, DTRM, Genentech, Johnson & Johnson, GenMAB, LOXO, Octopharma, Pharmacyclics, TG Therapeutics, Inc  Honorarium  Consultant Mato Speaker  AbbVie Inc., Aprea, AstraZeneca,  Research Support  Research DTRM, Genentech, Johnson & Johnson, GenMAB, LOXO, Octopharma, Pharmacyclics, TG Therapeutics, Inc  AstraZeneca, Daiichi‐Sankyo, Eli Lilly,  Honorarium/Travel McArthur Speaker  Advisory Board Merck & Co., Seattle Genetics Expenses  Amgen, EMD Serono Inc., Merck, Sharp & Dohme, Pfizer  Array BioPharma, Bristol‐Myers Squibb, EMD Serono Inc.,  Honorarium  Consultant Mehnert Speaker Sanofi/Regeneron  Honorarium  Advisory Board  Amgen, AstraZeneca, Bristol‐Myers  Research Grant  Research Squibb, EMD Serono, Immunocore, Incyte, Macrogenics, Merck, Novartis, Polynoma, Sanofi, Sharp & Dohme

Moeller Peer Reviewer  None  N/A  N/A

Moll Speaker  None  N/A  N/A

 Bristol‐Myers Squibb/Celgene, Genentech, Janssen, Novartis, TG Therapeutics  Research Support  Principle Investigator Nastoupil Speaker  Bayer, Bristol‐Myers Squibb/Celgene,  Honorarium  Advisory Board Genentech, Gilead/Kite, Janssen, Novartis, TG Therapeutics  Instrumentation Laboratory, Stago,  Research  Research Funding Siemens  Consultant Ortel Speaker  Honorarium  Instrumentation Laboratory  Chapter  Royalties  Up‐To‐Date Preparation/Review

Pal Speaker  None  N/A  N/A

Pierce Speaker  None  N/A  N/A

 AbbVie Inc., Amgen, AstraZeneca, Bristol‐Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Merck,  Honorarium  Consultant Ramalingam Speaker Takeda  Research Grant  Research  Advaxis, Amgen, AstraZeneca, Bristol‐ Myers Squibb, Merck, Takeda, Tesaro

Sherman Speaker  Eisai  Honorarium  Consultant

 Daiichi Sankyo, Deciphera, Eisai  Honorarium  Consultant  Expert Perspectives, OncLive  Honorarium  Speaker  Eli Lilly, Novartis  Honorarium  Speakers Bureau Singh Speaker  Blueprints, Eli Lilly, Roche  Honorarium  Advisory Board  Eli Lilly, Blueprints, Deciphera,  Research Support  Clinical Trail Nanocarrier  Stock Options  Board of Directors  Certis Oncology Solutions

Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology February 20‐21, 2021 ● Live Streaming Virtual Event

 AstraZeneca, Genomic Health,  Honorarium  Consultant Tripathy Speaker Immunomedica, OncoPep, Pfizer  Research Grant  Research  Novartis  Acerta Pharma/AstraZeneca, BeiGene, BioInvent, Bristol‐Myers Squibb/Celgene, Eli Lilly, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Loxo Oncology, Molecular Templates, VelosBio, Verastem,  AstraZeneca, Bristol‐Myers  Grant Funding  Principle Investigator Squibb/Celgene, Guidepoint Global,  Honorarium Wang Speaker  Consultant InnoCare, Janssen, Juno, Loxo, Kite  Honorarium/Travel  Speaker Pharma, MORE Health, Nobel Insight, Expenses Oncternal, Pharmacyclics, Pulse Biosciences  AstraZeneca, Beijing Medical Award Foundation, Dava Oncology, Janssen, Lu Daopei Medical Group, OMI, Pharmacyclics, Targeted Oncology  Informa (Taylor & Francis)  Royalties  Book Editor on HIT Warkentin Speaker  Aspen Global, Instrumentation  Honorarium  Consultant Laboratory, Law Firms Octapharma  Adaptive Biotech, Amgen, Bristol‐ Myers Squibb/Celgene, Genentech/Roche, Gilead, Janssen,  Honorarium  Consultant Novartis  Honorarium  Advisory Board Zelenetz Speaker  AbbVie, Inc., AstraZeneca,  Research Grants  Research Genentech, Gilead, MorphoSys,  Honorarium  DMC Chair  BeiGene, Gilead, MEI Pharma Roche  Honorarium  DMC Member  BeiGene  Bristol‐Myers Squibb, Celgene, Juno CME approval, all final decision‐ CME Committee  None  N/A  N/A making on courses Plan, manage, Scripps Conference implement, and  None  N/A  N/A Services & CME reconcile activity

Glossary of Terms

Commercial Interest The ACCME defines a “commercial interest” as any entity producing, marketing, re‐selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial Relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers’ bureau, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Conflict of Interest The ACCME considers financial relationships to create actual conflicts of interest in CME when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME considers “content of CME about the products or services of that commercial interest” to include content about specific agents/devices, but not necessarily about the class of agents/devices, and not necessarily content about the whole disease class in which those agents/devices are used. With respect to financial relationships with commercial interests, when a person divests themselves of a relationship it is immediately not relevant to conflicts of interest but it must be disclosed to the learners for 12 months.

Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology February 20‐21, 2021 ● Live Streaming Virtual Event

Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology February 20‐21, 2021 ● Live Streaming Virtual Event